Equities

Phase Holographic Imaging PHI AB

Phase Holographic Imaging PHI AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)3.99
  • Today's Change-0.09 / -2.21%
  • Shares traded4.50k
  • 1 Year change-43.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Phase Holographic Imaging PHI AB (PHI) is a Sweden-based company active in the field of medical technology. It develops and markets time-lapse cytometers for clinical applications. The products use holographic microscopy technology, with image sensors capturing light information from objects, and computer processing the information to create visual image. It is also engaged in the development of related software. Its method allows to view and measure living cell over time, without disturbing or destroying it. PHI collaborates with cancer- and stem cell researchers, among others. The Company’s product portfolio includes HoloMonitor M3, a bench-top time-lapse cytometer, and HoloMonitor M4, allowing cell analysis in the cultivation incubator.

  • Revenue in SEK (TTM)9.12m
  • Net income in SEK-21.81m
  • Incorporated1997
  • Employees14.00
  • Location
    Phase Holographic Imaging PHI ABSkiffervagen 48LUND 224 78SwedenSWE
  • Phone+46 46386080
  • Websitehttps://phiab.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Observe Medical ASA-98.28bn-98.28bn91.04m5.00--0.591----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
Dignitana AB86.49m-25.27m92.62m29.00--9.46--1.07-0.3268-0.32681.130.12151.742.7615.193,203,482.00-50.91-42.21-122.38-68.9169.5666.09-29.22-57.290.5202-9.970.609--17.9020.5922.52---15.31--
Glycorex Transplantation AB (publ)31.03m-27.83m92.82m15.00--2.54--2.99-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
Kontigo Care AB29.65m1.75m95.50m10.0042.951.9718.013.220.06940.06941.111.510.6241--8.03--3.68-0.42145.03-0.619569.9366.315.89-0.5205--10.000.0569--1.8016.95-92.68--44.94--
ScandiDos AB61.35m-9.67m96.92m26.00--2.22--1.58-0.2068-0.20681.260.7660.81841.316.881,978,871.00-12.90-12.60-23.54-21.7650.3951.58-15.76-15.370.9476-6.360.00---1.824.36-60.62---19.29--
SciBase Holding AB (publ)25.71m-59.24m98.79m27.00--1.87--3.84-0.4495-0.44950.18840.24090.2990.73284.04952,222.30-68.89-68.63-89.67-87.7770.0261.28-230.41-300.203.11-62.080.00--29.9327.50-28.75--5.15--
Luxbright AB4.20m-22.23m107.05m10.00--3.60--25.47-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Episurf Medical AB12.80m-79.70m107.42m26.00--1.06--8.39-0.2072-0.20720.03010.15580.1059--5.57457,142.80-66.09-47.46-75.45-52.01-----624.22-1,019.296.17--0.0296--53.6219.78-22.64---0.4158--
Iconovo AB2.92m-40.21m109.52m28.00--0.7354--37.55-2.74-2.740.1967.020.0215--1.14100,561.70-29.61-25.43-33.16-28.24635.97134.57-1,378.66-215.16---1,179.070.0668---58.65-9.884.71--34.70--
Phase Holographic Imaging PHI AB9.12m-21.81m111.48m14.00------12.22-0.8695-0.86950.3634-0.02730.23730.65981.18651,571.40-56.73-62.04-88.25-79.1671.0663.16-239.04-328.500.1916-5.611.04--6.1617.9612.98--22.76--
Immunovia AB (publ)885.00k-116.12m112.52m10.00--3.07--127.14-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Redsense Medical AB (publ)23.77m-3.98m115.11m5.00--3.58--4.84-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
BibbInstruments AB0.00-11.84m117.69m4.00--3.41-----0.4417-0.44170.001.180.00-------31.46-39.57-33.52-42.71--59.36---8,032.404.34--0.00------2.72---1.94--
Vo2 Cap Holding AB (publ)348.03m-55.15m119.45m94.00--0.6637--0.3432-0.9759-0.97596.463.160.7992--8.213,378,952.00-12.66-0.2564-17.29-0.383935.7823.36-15.84-0.2409---6.950.1429---26.0985.65-57.92---17.96--
Toleranzia AB0.00-7.12m135.21m11.00--0.6631-----0.0361-0.03610.000.75260.00----0.00-4.31-7.45-4.56-7.78------------0.0481------11.79--63.90--
SpectraCure AB (publ)2.36m-21.18m139.09m13.00--1.18--58.84-0.218-0.2180.02431.210.0166--24.63157,600.00-14.82-12.75-15.91-13.62442.39195.30-895.85-494.40----0.0494---3.30--19.46------
Data as of Nov 12 2024. Currency figures normalised to Phase Holographic Imaging PHI AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.